DAPAPHAGE-M FORTE Tablets
Composition:
DAPAPHAGE-M FORTE
- Each film coated tablet contains:
- Dapagliflozin propandiol U.S.P. equivalent to Dapagliflozin………………….……………..……..…. 10 mg
- Metformin Hydrochloride I.P. ……..…. 1000 mg (as sustained-release form)
- Excipients ……………………………………….……...... q.s.
- Colour – Yellow Oxide of Iron
Description
- DAPAPHAGE-M FORTE tackles the increase in blood glucose levels not controlled by monotherapy along with providing once a day dosage convenience. DAPAPHAGE-M FORTE contains two oral anti-hyperglycaemic drugs, Metformin Sustained-release and Dapagliflozin used in the management of Type 2 Diabetes.
- Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Dapagliflozin is a Sodium glucose co-transporter 2 inhibitor which maintains blood glucose level by preventing absorption of glucose by inhibiting sodium glucose transporter 2 in proximal tubule of nephrons in kidney.
- Hence, the combination of Metformin sustained-release and Dapagliflozin complement each other and provide better glycaemic control in the management of Type 2 Diabetes and probably helps in the prevention of diabetes-associated macrovascular and microvascular complications.
Indications
- DAPAPHAGE-DAPAPHAGE- FORTE™ is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with T2DM who are already treated with a combination of dapagliflozin and metformin, given separately, or whose diabetes is not adequately controlled with metformin alone, or for those patients who have initially responded to dapagliflozin alone and require additional glycaemic control.